Sign In
Buy TRCK
$0.643
-0.0072 (-1.11%)
At Close: Jul 31, 2026
Berkshire Hathaway: Impressed By G. Abel's Track Record
07:04am, Wednesday, 10'th Sep 2025
Warren Buffett's planned departure and Greg Abel's succession have raised investor concerns, contributing to Berkshire's 20% underperformance vs. the market. Abel has delivered ~12% returns at Berkshi
Is Modine on Track to Reach $2B in Data Center Revenues by 2028?
12:01pm, Tuesday, 09'th Sep 2025
MOD targets $2B in data center revenues by 2028 with a $100M U.S. expansion plan focused on capacity growth and innovation.
Fulgent Genetics: Core Growth Re-Acceleration And Gross Margin Expansion Are On Track (Reiterate Buy)
01:58pm, Monday, 08'th Sep 2025
While the stock price is unchanged since my buy rating a year ago, revenue growth is accelerating (FY25E: +14%) and gross margins are going up (FY25E: 40%, +200bps vs PY). Both precision diagnostics a
Societe Generale: On Track To Achieve 2026 Financial Targets
02:12am, Sunday, 07'th Sep 2025
Societe Generale has benefited from recent profitability improvements in French retail and mobility/international retail segments. At the same time, the Capital Markets/Investor Solutions segment did
CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)
08:00am, Friday, 05'th Sep 2025
Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company's lead cancer immunotherapy program
3 Growth Stocks on Track to Reach a $300 Billion Valuation by 2026
05:50am, Friday, 05'th Sep 2025
While there is a lot of talk and attention focused on trillion-dollar companies, the fact of the matter is that, as of Sept. 3, only 34 publicly traded companies (out of more than 10,500 international
Gold (XAU/USD) Price Forecast: Rally Pauses, Weekly Breakout Still on Track
04:58pm, Thursday, 04'th Sep 2025
Gold eased Thursday, dipping toward $3,500 support after reaching $3,578 Wednesday. Despite the pullback, weekly and monthly signals confirm strong demand, keeping higher breakout targets in play.
STOCKHOLM , Sept. 2, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated a rolling submission of the Supplemental Biologics Lic
Chipotle's Margins Slip: Can $4 Million AUV Goal Stay on Track?
10:46am, Monday, 01'st Sep 2025
CMG's margins are down in the second quarter, but efficiency upgrades and catering expansion can be a key to sustaining its $4 million AUV target.
Allarity Therapeutics shares pop as ovarian cancer therapy recieves FDA Fast Track Designation
11:47am, Tuesday, 26'th Aug 2025
Allarity Therapeutics (NASDAQ:ALLR) shares more than doubled after the pharmaceutical firm annoucned that its investigational therapy for advanced ovarian cancer, stenoparib, has received Fast Track D
Sekur Private Data Ltd. On Track for Corporate and Premium Solutions Rollout in September 2025
08:30am, Tuesday, 26'th Aug 2025
New Plans to Increase Sekur's Marketshare and Sales Globally - Targeting VIPs, C-Level Execs and Governments VANCOUVER, BC / ACCESS Newswire / August 26, 2025 / Sekur Private Data Ltd. (OTCQB:SWISF)(C
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
08:00am, Tuesday, 26'th Aug 2025
TARPON SPRINGS, Fla., August 26, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing steno
Biohaven: Despite Troriluzole Program Delay, FDA Review On Track For Q4 2025
08:00am, Monday, 25'th Aug 2025
Biohaven's troriluzole shows 50%-70% slowing of SCA disease progression, with FDA review now on track for Q4 2025 after a brief delay. FDA is no longer requiring an advisory committee meeting to revie
Viking: Still On Track, But The Compass Needs Recalibration
06:57am, Saturday, 23'rd Aug 2025
Viking's oral VK2735 efficacy was strong, but tolerability issues and high discontinuation rates cloud its competitive edge in the obesity drug market. The market's perception of Viking shifted after
Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track
03:45pm, Thursday, 21'st Aug 2025
Celldex Therapeutics, Inc.'s barzolvolimab failed to improve symptoms in eosinophilic esophagitis, but this setback doesn't impact its promising ongoing urticaria programs. Phase 3 trials for chronic
